Molecularly characterising triple negative breast cancer
Molecularly characterising triple negative breast cancer
Endocrine therapy and endocrine resistant breast cancer
Neoadjuvant therapy and PCR through chemotherapy prior to surgery
Minimising recurrence by using most effective treatment
Overcoming drug resistance and targeting critical pathways
Heterogeneity of tumours and the challenges of biomarker development
Targeting the PI3K/mTOR pathway
Use of metformin against breast cancer
Cancer genes differ in different parts of a tumour
Targeting DNA damage response and repair excluding PARP for triple negative breast cancer
Endocrine therapy resistance and next generation sequencing
Molecular characterisation of breast cancer: the mutational landscape